Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection in the Treatment of Ventricular Tachycardia and Ventricular Fibrillation. A Multicenter, Randomized, Controlled, Open-label, Clinical Trial.

NCT03855826 is registered in ClinicalTrials.gov with Sichuan Baili Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03855826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03855826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection in the Treatment of Ventricular Tachycardia and Ventricular Fibrillation. A Multicenter, Randomized, Controlled, Open-label, Clinical Trial.
Lead sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase
Phase 4
Overall status
Unknown status
Start date
January 15, 2019
Completion date
January 30, 2020
Enrollment
756 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ventricular fibrillation, ventricular tachycardia